AbstractPurpose:. Patients with endometrial cancer who progress after chemotherapy/immunotherapy have limited treatment options. We evaluated the activity and safety of sacituzumab govitecan (SG), a T...

Abstract. Purpose: Access to early-phase clinical trials (EPCTs) is increasingly constrained by delays in genomic testing and lack of coordinated system-level navigation. The New South Wales Early Pha...

Research presented at the AACR Annual Meeting 2026 showed that wildfire smoke exposure was associated with an increased cancer risk.

Abstract. Purpose: The PI3K/AKT pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphat...

AbstractPurpose:. Docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease, but benefits vary substantially among patients. Without predictiv...

Abstract. Purpose: To evaluate the combination of intra-tumoral Delta-24-RGD and subcutaneous interferon gamma (IFN-g) in patients with high grade glioma (HGG), based on the rationale that augmenting ...

Abstract. Dosage selection for oncology drugs has traditionally relied on initial dose-finding trials to determine a maximum tolerated dose (MTD), which is then further evaluated in approval-supportin...

Abstract. The maximum tolerated dose has historically been the recommended phase two dose, and this dosage has typically been evaluated in registrational clinical trials for oncology drugs. With the e...

Abstract. Dosage optimization has become a focus in oncology drug development, as highlighted by recent U.S. Food and Drug Administration initiatives including Project Optimus. Traditionally, most onc...

In July 2025, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.